Market Overview

UPDATE: JP Morgan Upgrades Thermo Fisher Scientific to Overweight on Favorable Risk/Reward

Share:
Related TMO
Barron's Picks And Pans: Kinder Morgan, Gilead Sciences And More
Earnings Scheduled For January 28, 2016
MedTech Series: Why Medical Technology Companies Should Have A Place In Your Portfolio (Seeking Alpha)

JP Morgan upgraded Thermo Fisher Scientific (NYSE: TMO) from Neutral to Overweight and raised the price target from $70.00 to $80.00.

JP Morgan noted, "We are upgrading Thermo Fisher Scientific (TMO) from Neutral to Overweight on favorable risk/reward due to conservative guidance that should be at worst achievable, and more likely beatable, and an improving record of capital deployment since management has increasingly focused on the higher bar of ROIC, rather than simply adjusted EPS accretion. The company's robust and growing free cash flow provides clear optionality around additional capital deployment, including but not limited to recent press reports (Reuters) that it is now evaluating a purchase of Life Technologies (LIFE)."

Thermo Fisher Scientific closed at $72.14 on Thursday.

Latest Ratings for TMO

DateFirmActionFromTo
Jan 2016Deutsche BankInitiates Coverage onBuy
Jan 2016Avondale PartnersInitiates Coverage onMarket Outperform
Jul 2015BairdMaintainsOutperform

View More Analyst Ratings for TMO
View the Latest Analyst Ratings

Posted-In: JP MorganAnalyst Color Upgrades Analyst Ratings

 

Related Articles (TMO)

Get Benzinga's Newsletters